TITLE

Boston Sci to pay $195 million to settle Guidant device claims

PUB. DATE
August 2007
SOURCE
Cardiovascular Device Update;Aug2007, Vol. 13 Issue 8, p20
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Boston Scientific will pay for claims regarding the implantable rhythm management devices made by Guidant. Boston Scientific will allot $195 million to settle claims of patients who were implanted with the devices. The devices were recalled by Guidant because of possible failure. Guidant was acquired by Boston in 2006.
ACCESSION #
26481794

 

Related Articles

  • Boston Sci undertakes initiative to measure data from Latitude.  // Cardiovascular Devices & Drugs;May2008, Vol. 14 Issue 5, p40 

    The article reports on the announcement by Boston Scientific of a clinical science initiative called Altitude which will analyze data from the Latitude patient management system. The initiative aims to seek answers to common questions related to implantable cardiac defibrillator (ICD) and the...

  • Boston Scientific ICD recalls.  // Materials Management in Health Care;Aug2006, Vol. 15 Issue 8, p8 

    The article reports that Massachusetts-based Boston Scientific Corp. is continuing the recall of certain models of cardiac resynchronization pacemakers and implantable cardioverter defibrillators produced by Guidant, which was acquired by Boston. The United States Food and Drug Administration...

  • Boston Sci sees up-tick in Guidant ICD-related suits.  // Medical Technology & Devices Week;3/12/2007, Vol. 5 Issue 11, p3 

    The article focuses on reports from Boston Scientific about the increase in the number of lawsuits against Guidant's heart rhythm devices. The company now faces more than 1,100 individual and 75 class action lawsuits over recalls and safety warnings issued in 2005 and 2006 involving Guidant's...

  • U.S. FOOD & DRUG ADMINISTRATION UPDATE.  // Materials Management in Health Care;Sep2009, Vol. 18 Issue 9, p6 

    The article offers updates on the U.S. food and drug administration. The 38-millimeter version of the Taxus Liberte drug-eluting stent from Boston Scientific Corp. in Natick, Massachusetts received the approval for its use. Certain Hospira devices with defective AC power cords made by...

  • BSI receives approval for patient management tech.  // Medical Device Daily;11/24/2010, Vol. 14 Issue 229, p1 

    The article reports that the Latitude patient management system of Boston Scientific has been given regulatory approval in Australia and New Zealand. The system will help physicians remotely monitor patients who have implantable cardiac devices. The American College of Cardiology and American...

  • Boston Scientific swallows Guidant. Murphy, Tom // Indianapolis Business Journal;1/1/2007, Vol. 27 Issue 44, p5 

    The article reports that Indianapolis, Indiana-based medical instrument manufacturer Guidant Corp. has been acquired by Massachusetts-based Boston Scientific Corp. for twenty seven billion dollars. The deal had a negative impact for Boston Scientific in terms of a 40 percent decline in stock...

  • FDA gives blessing to defribrillator device. Mauer, Katie // Indianapolis Business Journal;11/17/2003, Vol. 24 Issue 36, p33A 

    Reports on Guidant Corp.'s announcement that it has received regulatory approval for a line of products used with cardiac implants. Description of the Endotal Reliance G defibrillation leads; Other Guidant products approved by the FDA.

  • Boston Scientific receives the CE mark for pacemakers.  // Medical Device Daily;4/11/2012, Vol. 16 Issue 70, p1 

    The article reports on the CE mark approval received by Boston Scientific for its pacemakers. The company has launched its Ingenio and Advantio pacemakers and Invive cardiac resynchronization therapy pacemakers (CRT-P) in Europe. Doctor Marc Burban performed one of the first implants of the...

  • First implants for Cognis and Teligen CRT-D devices In Europe.  // Cardiovascular Devices & Drugs;Mar2008, Vol. 14 Issue 3, p16 

    The article reports that the first European implants of Boston Scientific's Cognis cardiac resynchronization therapy defibrillator (CRT-D) and Teligen implantable cardioverter defibrillator (ICD) has been conducted. According to the company, the cardiac devices are designed to eliminate the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics